HER2-Low Breast Cancer: Current Landscape and Future Prospects

More than 50% of breast cancers are currently defined as “Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)”, with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. In most studies that compared the clinical and bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirman, Yelena, Lubovsky, Shlomit, Shai, Ayelet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439285/
https://www.ncbi.nlm.nih.gov/pubmed/37600670
http://dx.doi.org/10.2147/BCTT.S366122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439285/
https://www.ncbi.nlm.nih.gov/pubmed/37600670
http://dx.doi.org/10.2147/BCTT.S366122

Ejemplares similares